[go: up one dir, main page]

NO20085147L - Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin - Google Patents

Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin

Info

Publication number
NO20085147L
NO20085147L NO20085147A NO20085147A NO20085147L NO 20085147 L NO20085147 L NO 20085147L NO 20085147 A NO20085147 A NO 20085147A NO 20085147 A NO20085147 A NO 20085147A NO 20085147 L NO20085147 L NO 20085147L
Authority
NO
Norway
Prior art keywords
treatment
resistant
oridonin
composition
present
Prior art date
Application number
NO20085147A
Other languages
English (en)
Inventor
Sophie Chen
Original Assignee
Activephyto Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activephyto Technologies Ltd filed Critical Activephyto Technologies Ltd
Publication of NO20085147L publication Critical patent/NO20085147L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelse vedrører behandling av terapi-resistente neoplasier. Forbindelsene og metodene ifølge oppfinnelsen er særlig anvendelige for behandling av taxol-resistente menneske-kreftformer, særlig cervical og brystkreft. Komponentene i blandingene ifølge den foreliggende oppfinnelse viser sterk synergisme med hverandre, hvilket gjør det mulig å anvende i relativt lave mengder for behandling av trinn IV eller tilbakevendende kreft som kan ha blitt resistent overfor de tradisjonelle kjemoterapeutiske midler. Disse blandinger omfatter oridonin.
NO20085147A 2006-05-11 2008-12-10 Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin NO20085147L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0609386.8A GB0609386D0 (en) 2006-05-11 2006-05-11 Treating drug resistant cancers
PCT/GB2007/001720 WO2007132190A1 (en) 2006-05-11 2007-05-10 Composition for the treatment of resistant cancers comprising oridonin

Publications (1)

Publication Number Publication Date
NO20085147L true NO20085147L (no) 2009-02-09

Family

ID=36637342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085147A NO20085147L (no) 2006-05-11 2008-12-10 Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin

Country Status (15)

Country Link
US (1) US9089546B2 (no)
EP (1) EP2026780A1 (no)
JP (1) JP2009536635A (no)
KR (1) KR20090037395A (no)
CN (1) CN101495108B (no)
AU (1) AU2007251374A1 (no)
BR (1) BRPI0712788A2 (no)
CA (1) CA2651795A1 (no)
GB (1) GB0609386D0 (no)
IL (1) IL195039A0 (no)
MX (1) MX2008014395A (no)
NO (1) NO20085147L (no)
RU (1) RU2455002C2 (no)
SG (1) SG171583A1 (no)
WO (1) WO2007132190A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
FR2944435B1 (fr) 2009-04-17 2011-05-27 Sederma Sa Composition cosmetique comprenant de l'oridonine
EP2760547B1 (en) 2011-09-30 2022-11-16 Perio Sciences, LLC Antioxidant compositions for treatment of inflammation or oxidative damage
CN102648956A (zh) * 2012-05-18 2012-08-29 漳州市中草药研究所 一种治疗乳腺癌的中草药制剂及其制备方法
WO2014047780A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资（香港）有限公司 含有芹菜素及芹菜素类衍生物和冬凌草甲素及冬凌草甲素类衍生物的药物组合物及其应用
CN104434939B (zh) * 2014-11-14 2017-05-03 深圳大学 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用
WO2019005829A1 (en) * 2017-06-26 2019-01-03 Wayne State University METHODS AND COMPOSITIONS RELATING TO CANCER DEPENDENT ON HORMONE RECEPTORS
KR101948247B1 (ko) * 2017-07-14 2019-02-14 한국생명공학연구원 Oct4 저해용 조성물 및 이의 용도
EP3881846A4 (en) * 2018-11-16 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION WITH PARP INHIBITORS
KR102263396B1 (ko) * 2019-11-01 2021-06-10 가톨릭관동대학교산학협력단 이소리퀴리티제닌 유도체를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물
CN111467367B (zh) * 2020-05-22 2021-08-17 陈炯 一种用于抑制肿瘤细胞生长的植物单体组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476016A (en) * 1975-07-31 1977-06-10 Nippon Shinyako Co Ltd Pharmaceutical compositions having anti-tumour activity
IT1271301B (it) * 1994-12-20 1997-05-27 Indena Spa Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
US20030035851A1 (en) * 2001-02-08 2003-02-20 Sophie Chen Anti-cancer agents and method of use thereof
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
CN1220519C (zh) * 2002-08-26 2005-09-28 上海中耀生物科技有限公司 治疗前列腺癌的中药组合物及其制备方法和制药应用
WO2004080474A1 (en) 2003-03-06 2004-09-23 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising prenyl flavonoids

Also Published As

Publication number Publication date
EP2026780A1 (en) 2009-02-25
US9089546B2 (en) 2015-07-28
GB0609386D0 (en) 2006-06-21
SG171583A1 (en) 2011-06-29
IL195039A0 (en) 2009-08-03
CN101495108B (zh) 2014-10-15
CA2651795A1 (en) 2007-11-22
KR20090037395A (ko) 2009-04-15
CN101495108A (zh) 2009-07-29
WO2007132190A1 (en) 2007-11-22
AU2007251374A1 (en) 2007-11-22
RU2008148833A (ru) 2010-06-20
MX2008014395A (es) 2009-04-23
US20100016420A1 (en) 2010-01-21
RU2455002C2 (ru) 2012-07-10
JP2009536635A (ja) 2009-10-15
BRPI0712788A2 (pt) 2012-09-11

Similar Documents

Publication Publication Date Title
NO20085147L (no) Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
HRP20080377B1 (hr) ANTAGONISTI AKTIVIN-ActRIIa I PRIMJENE ZA STIMULACIJU RASTA KOSTI
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20092637L (no) Fremgangsmater for behandling
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20074446L (no) DR5-antistoffer og anvendelser derav
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
EP2476461A3 (en) Formulations For Cancer Treatment
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
MY143795A (en) Tetrahydropyridoindole derivatives
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
MX2009011822A (es) Hidroxi sulfonatos de compuestos de quinonicos y sus usos.
EP2402321A3 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
MX2009004436A (es) Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application